OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Baljevic on Key Considerations for Treatment Selection in Newly Diagnosed Multiple Myeloma

May 23rd 2024

Muhamed Baljevic, MD, discusses the consideration of patient comorbidities and preferences during treatment selection in newly diagnosed myeloma.

Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma

May 23rd 2024

Sumanta Kumar Pal, MD, FASCO, discusses key biomarker analyses in renal cell carcinoma that will be presented at the 2024 ASCO Annual Meeting.

Dr Kitko on the Utility of Obe-Cel in Pediatric Patients With B-ALL

May 23rd 2024

Carrie L. Kitko, MD, discusses the use of obecabtagene autoleucel for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr Maxwell on Real-World Germline Variant Rates in Prostate Cancer

May 23rd 2024

Kara N. Maxwell, MD, PhD, discusses key takeaways from a real-world investigation of germline mutation rates in patients with metastatic prostate cancer.

Dr Lim on Multidisciplinary Approaches to Pancreatic Cancer Management

May 23rd 2024

Kian-Huat Lim, MD, PhD, discusses the importance of multidisciplinary collaboration when diagnosing and treating patients with pancreatic cancer.

Dr Gajewski on the Role of the Gut Microbiome in Immunotherapy Response Regulation

May 22nd 2024

Thomas F. Gajewski, MD, PhD, discusses the mechanism through which the gut microbiome modulates myeloid cells to regulate responses to immunotherapy.

Dr Krogsgaard on Phosphorylated Neoantigen Targets for Anticancer Vaccine Development

May 22nd 2024

Michelle Krogsgaard, PhD, discusses the identification and potentially utility of phosphorylated neoantigen targets for anticancer vaccine development.

Dr Leslie on the Utility of Axi-cel in High-Risk LBCL

May 22nd 2024

Lori A. Leslie, MD, discusses the utility of treatment with axi-cel through the lens of the ZUMA-7 trial in large B-cell lymphoma.

Dr Shitara on the Background of the CheckMate 649 Trial in GEJ Adenocarcinoma

May 22nd 2024

Kohei Shitara, MD, discusses the background of the phase 3 CheckMate 649 study in advanced gastric cancer, GEJ cancer, and esophageal adenocarcinoma.

Dr Tiwari on the Current Treatment Paradigms for HER2-Positive and HER2-Low Breast Cancers

May 22nd 2024

Shruti Tiwari, MD, discusses how the treatment paradigms for HER2-positive and HER2-low breast cancer has evolved in recent years.

Dr Bou Farhat on a Retrospective Study of NGS vs IHC Sensitivity for dMMR CRC and Endometrial Cancer

May 22nd 2024

Elias Bou Farhat, MD, discusses an investigation of NGS sensitivity vs standard IHC alone in the assessment of dMMR colorectal cancer or endometrial cancer.

Dr Neelapu on Addressing CAR T-Cell Resistance in Lymphoma

May 22nd 2024

Sattva S. Neelapu, MD, discusses mechanisms of resistance to CAR T-cell therapies in lymphoma and how these areas of need may be addressed.

Dr Jagannath on Safety Considerations With Ide-Cel in Multiple Myeloma

May 20th 2024

Sundar Jagannath, MBBS, discusses the FDA’s ODAC Meeting on safety considerations with ide-cel in multiple myeloma.

Dr Maxwell on the Accessibility of Genetic Testing in Metastatic Prostate Cancer

May 20th 2024

Kara N. Maxwell, MD, PhD, discusses the accessibility of genetic testing in the community setting for patients with metastatic prostate cancer.

Dr Lim on the Treatment of Resectable and Borderline Resectable Pancreatic Cancer

May 20th 2024

Kian-Huat Lim, MD, PhD, discusses the current standard of care for patients with resectable or borderline resectable pancreatic cancer.

Dr Kelly on ctDNA Dynamics Following Neoadjuvant Immunotherapy in GEJ Cancer

May 20th 2024

Ronan J. Kelly, MD, MBA, FASCO, discusses the predictive value of ctDNA following neoadjuvant immunotherapy in resectable gastroesophageal cancer.

Dr Salani on Research With MEK Inhibition in KRAS-Mutant Serous Ovarian Cancer

May 20th 2024

Ritu Salani, MD, MBA, discusses pathways implicated in low-grade serous ovarian cancer that may be viable for targeted therapy development.

Dr Lattanzi on Findings From the PROpel trial in mCRPC

May 17th 2024

Mike Lattanzi, MD, discusses key findings from and implications of the PROpel trial in patients with metastatic castration-resistant prostate cancer.

Dr Narayan on Long-Term Results With Nadofaragene Firadenovec in NMIBC

May 17th 2024

Vikram M. Narayan, MD, discusses the final 5-year analysis of a phase 3 trial of nadofaragene firadenovec in patients with BCG-unresponsive NMIBC.

Dr Liu Previews ASCO 2024 Lung Cancer Data

May 17th 2024

Stephen V. Liu, MD, discusses studies being presented at the 2024 ASCO Annual Meeting that may provide valuable insights into the management of NSCLC.